- Home
- Equipment
- australasia
- clinical candidate developed
Refine by
Clinical Candidate Developed Equipment Supplied In Australasia
7 equipment items found
Manufactured by:Orthocell Ltd. based inMurdoch, AUSTRALIA
Orthocell’s OrthoATI™ is a cell therapy for treatment of chronic degenerative tendon injuries. OrthoATI™ addresses a significant unmet clinical need for a non-surgical solution for a debilitating injury affecting millions of people every year. OrthoATI™ addresses the underlying pathology of tendon injury, replenishing degenerative tissue with healthy mature tendon ...
Manufactured by:Avania based inBrunswick, AUSTRALIA
Biotechnology research is an ever-evolving area of science that requires nimble teams and customized solutions. We have a track record of developing advanced therapeutics with limited resources and tight timelines. Our team has extensive biotech and pharma experience from the sponsor side, so we know what you need from us to ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
INOVIQ has three autoantibody tests in development for early detection of ovarian, breast and lung cancers. BARD1 autoantibody tests measure autoantibodies to variant BARD1 proteins in the blood and use a proprietary cancer-specific algorithm to combine these levels into a cancer score that identifies the presence or absence of a specific cancer. BARD1 autoantibodies reflect the body’s ...
Manufactured by:LISCure Biosciences Inc. based inSeongnam-si, SOUTH KOREA
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening Platform, Microbial Optimization Platform, and Microbiome Database ...
Manufactured by:NeuroScientific Biopharmaceuticals Ltd. based inCottesloe, AUSTRALIA
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt neurodegeneration. We believe that EmtinB has potential to bridge this gap and bring this breakthrough medicine to clinics, bringing new hope to ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. Following further development, AdAlta ...
Manufactured by:Biotron Limited based inNorth Ryde, AUSTRALIA
Biotron is developing novel small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and ...